This Market Spotlight report covers the chemotherapy-induced anemia market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, probability of success, epidemiology information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• Chemotherapy-induced anemia (CIA) is a common complication in cancer patients receiving chemotherapy. The prevalence of CIA is difficult to determine due to inconsistencies in definition and variations in the severity of anemia, region, cancer type, and stage.
• All of the approved drugs for CIA target the erythropoietin receptor. These drugs are all administered via both the intravenous and subcutaneous routes.
• The only industry-sponsored drug in active clinical development for CIA is in Phase III.
• The only therapy in development for CIA targets hypoxia-inducible factor-prolyl hydroxylase. It is administered via the oral route. The overall likelihood of approval of a Phase I marrow or peripheral blood stimulator asset is 22.5%, and the average probability a drug advances from Phase III is 82.5%. Drugs, on average, take 10.1 years from Phase I to approval, compared to 9.7 years in the overall hematology space.
• The distribution of clinical trials across Phase I–IV indicates that the majority of trials for CIA have been in the late phases of development, with 61% of trials in Phase III–IV, and 39% in Phase I–II.
• Clinical trial activity in the CIA space is dominated by completed trials. Amgen has the highest number of completed clinical trials for CIA, with 66 trials.
• Amgen leads industry sponsors with the highest overall number of clinical trials for CIA, followed by Johnson & Johnson.